Veeva price target raised to $275 from $268 at Truist

Truist raised the firm’s price target on Veeva (VEEV) to $275 from $268 and keeps a Hold rating on the shares. The company reported strong “beat and raise” Q2 results, though the company’s guidance continues to assume no significant changes in the macro environment in the near term, the analyst tells investors in a research note. Regarding Vault CRM, seven of the top 20 biopharmas have committed to Vault CRM, with two additional verbal commitments from the group, versus Salesforce (CRM), which currently has two top 20 commitments and one verbal commitment, the firm added.